iData Insights

Myocardial Infarction - Pipeline Review, H2 2015 Now Available at iData Insights

Press Release   •   Dec 01, 2015 16:27 IST

Myocardial Infarction - Pipeline Review, H2 2015 Summary Global Markets Direct s, Myocardial Infarction - Pipeline Review, H2 2015, provides an overview of the Myocardial Infarctions therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Myocardial Infarction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myocardial Infarction and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Myocardial Infarction - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Myocardial Infarction and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Myocardial Infarction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Myocardial Infarction pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Myocardial Infarction - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Myocardial Infarction pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Browse Complete Report with TOC @http://www.idatainsights.com/reports-landing-page.php?id=124186/myocardial-infarction-pipeline-review-h2-2015

To Get Sample Copy of Report visit @http://www.idatainsights.com/reports-landing-page.php?id=124186/myocardial-infarction-pipeline-review-h2-2015

Table of Contents

Table of Contents

2 List of Tables

7 List of Figures

9 Introduction

10 Global Markets Direct Report Coverage

10 Myocardial Infarction Overview

11 Therapeutics Development

12 Pipeline Products for Myocardial Infarction - Overview

12 Pipeline Products for Myocardial Infarction - Comparative Analysis

13 Myocardial Infarction - Therapeutics under Development by Companies

14 Myocardial Infarction - Therapeutics under Investigation by Universities/Institutes

20 Myocardial Infarction - Pipeline Products Glance

21 Late Stage Products

21 Clinical Stage Products

22 Early Stage Products

23 Unknown Stage Products

24 Myocardial Infarction - Products under Development by Companies

25 Myocardial Infarction - Products under Investigation by Universities/Institutes 31 Myocardial Infarction - Companies Involved in Therapeutics Development

33 Alligator Bioscience AB 33 Amarantus Bioscience Holdings, Inc.

34 Angion Biomedica Corp.

35 Aprogen, Inc.

36 APT Therapeutics, Inc.

37 AstraZeneca Plc

38 Athersys, Inc.

39 Bayer AG

40 Bharat Biotech International Limited

41 BioLineRx, Ltd.

42 Biscayne Pharmaceuticals, Inc.

43 CellProthera

44 Celyad

45 ChemoCentryx, Inc.

46 Compugen Ltd.

47 CSL Limited 48 FibroGen, Inc.

49 Fina Biotech

50 Hadasit Medical Research Services & Development Ltd

51 Human Stem Cells Institute

52 HUYA Bioscience International, LLC

53 Immune Pharmaceuticals Inc.

54 Inbiopro Solutions Pvt. Ltd.

55 Juventas Therapeutics, Inc.

56 Laboratoires Pierre Fabre SA

57 Lacer, S.A.

58 Lee's Pharmaceutical Holdings Limited

59 LegoChem Biosciences, Inc

60 LG Life Sciences, Ltd.

61 Medestea Research & Production S.p.A.

62 Mesoblast Limited

63 miRagen Therapeutics, Inc.

64 NeuroVive Pharmaceutical AB

65 Omeros Corporation 66 Omni Bio Pharmaceutical Inc. 67 Otsuka Holdings Co., Ltd. 68 Polyphor Ltd. 69 Quantum Genomics SA

70 Recardio GmbH

71 Remedy Pharmaceuticals, Inc.

72 Serodus ASA

73 STELIS Biopharma Pvt. Ltd.

74 Stemedica Cell Technologies, Inc.

75 Stempeutics Research Private Limited

76 TaiGen Biotechnology Co., Ltd.

77 Targazyme, Inc.

78 The International Biotechnology Center (IBC) Generium

79 TiGenix NV 80 Vicore Pharma AB 81 Virocan Therapeutics Private Limited

82 Yuyu Pharma, Inc. 83 Zealand Pharma A/S

84 Zydus Cadila Healthcare Limited

85 Myocardial Infarction - Therapeutics Assessment

86 Assessment by Monotherapy Products

86 Assessment by Target

87 Assessment by Mechanism of Action 91 Assessment by Route of Administration

94 Assessment by Molecule Type 96 Drug Profiles 98 ADC-1004 - Drug Profile

98 Alda-1 - Drug Profile 99 Alpha-1 Antitrypsin - Drug Profile

100 alteplase biosimilar - Drug Profile

102 AMRS-001 - Drug Profile

103 AmVimi-007 - Drug Profile

105 ANG-4011 - Drug Profile

106 AP-102 - Drug Profile

107 APT-102 - Drug Profile

108 balixafortide - Drug Profile

110 Biosimilar 3 for Rheumatoid Arthritis and Acute Myocardial Infarction - Drug Profile

111 Biosimilar 4 for Acute Myocardial Infarction and Infertility - Drug Profile

112 BIS-5409 - Drug Profile

113 Bone Marrow Derived Mononuclear Cells for Cardiovascular Diseases - Drug Profile

114 burixafor - Drug Profile

116 C-21 - Drug Profile

118 C3BSGQR-3 - Drug Profile

120 C3BSGQR-4 - Drug Profile

121 CAP-1001 - Drug Profile

122 CAP-1002 - Drug Profile 123 CCX-872 - Drug Profile

125 cenderitide - Drug Profile

126 CGEN-856 - Drug Profile 128 CGEN-856S - Drug Profile

129 CIGB-500 - Drug Profile

131 CM-1 - Drug Profile

132 Cryocell - Drug Profile

134 CSL-112 - Drug Profile

135 CTX-101 - Drug Profile

137 CTX-201 - Drug Profile

139 cyclosporine - Drug Profile

140 danegaptide - Drug Profile

141 Drugs to Inhibit Alpha Myosin for Cardiovascular Disorders - Drug Profile

142 Drugs to Inhibit Sir2 Protein for Ischemic Stroke and Myocardial Infarction - Drug Profile

143 dutogliptin tartrate - Drug Profile

144 Ephrin A-1 for Myocardial Infarction - Drug Profile

146 F-573 - Drug Profile

147 Fc-Alpha-1 Antitrypsin - Drug Profile

148 FcAAT-2 - Drug Profile

149 FcAAT-3 - Drug Profile

150 FG-6874 - Drug Profile

151 Gemacell - Drug Profile

152 Gene Therapy for Acute Myocardial Infarction - Drug Profile

153 glyburide - Drug Profile

154 HBI-3802 - Drug Profile

156 HYPER-IL-6 - Drug Profile

157 IBPB-005ET - Drug Profile

158 ICG-001 - Drug Profile

159 IS-20 - Drug Profile

160 JI-38 - Drug Profile

161 JVS-100 - Drug Profile

162 JVS-200 - Drug Profile

164 KR-33028 - Drug Profile

165 LA-8045 - Drug Profile

166 LC-280126 - Drug Profile

167 Mesenchymal Stem Cells - Drug Profile

169 MGN-1374 - Drug Profile

171 MGN-6114 - Drug Profile

172 Monoclonal Antibody Conjugates to Target Mannose Receptor for Myocardial Infarction - Drug Profile

173 MPC-150IM - Drug Profile

174 MPC-25IC - Drug Profile

176 MTP-131 - Drug Profile

177 MultiStem - Drug Profile

179 NVP-019 - Drug Profile

183 Oligonucleotide for Oncology and Cardiovascular - Drug Profile

184 Oligonucleotides for Cardiometabolic Diseases and Renal diseases - Drug Profile

185 OMS-721 - Drug Profile

186 OPC-28326 - Drug Profile

188 Peptide to Activate Erythropoietin Receptor for Cardiovascular Diseases - Drug Profile

190 Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction - Drug Profile

191 Polyglactin 370 for Acute Myocardial Infarction - Drug Profile

192 Protein for Cardiovascular Diseases - Drug Profile

193 ProtheraCytes - Drug Profile

194 QGC-101 - Drug Profile

196 RBB-001 - Drug Profile

197 Recombinant Protein for Myocardial Infarction - Drug Profile

198 Recombinant Proteins to Agonize IGF-1R for Myocardial Infarction - Drug Profile

199 Recombinant Prourokinase - Drug Profile

200 remestemcel-L - Drug Profile

201 rivaroxaban - Drug Profile 204 RNAi Oligonucleotide for Myocardial Infarction - Drug Profile

209 RNAi Oligonucleotide for Myocardial Infarction - Drug Profile

210 SBL-004 - Drug Profile

211 SER-130 - Drug Profile

212 Small Molecule for Myocardial Infarction - Drug Profile

213 Small Molecule to Inhibit Blood Factor XIa for CAHD and Stroke - Drug Profile

214 Small Molecules for Myocardial Infarction and Inflammation - Drug Profile

215 Small Molecules to Antagonize Adenosine A2B Receptor for Asthma and Myocardial Infarction - Drug Profile

216 Small Molecules to Inhibit BAX for Myocardial Infarction - Drug Profile

217 Small Molecules to Inhibit MMP for Myocardial Infarction - Drug Profile

218 Small Molecules to Inhibit PARP for Immunology, Oncology, Cardiovascular and Metabolic Disorders - Drug Profile 219 Stem Cell Therapy for Cardiovacular Diseases - Drug Profile

220 Stem Cell Therapy for Myocardial Infarction - Drug Profile

221 Stem Cells for Acute Myocardial Infarction - Drug Profile

223 Stempeucel - Drug Profile

224 Synthetic Peptide for Cardiovascular Diseases - Drug Profile

227 THR-100 - Drug Profile 228 ticagrelor - Drug Profile

230 TZ-101 - Drug Profile

234 VN-100 - Drug Profile

236 ZK-001 - Drug Profile

237 Myocardial Infarction - Recent Pipeline Updates

239 Myocardial Infarction - Dormant Projects

308 Myocardial Infarction - Discontinued Products

315 Myocardial Infarction - Product Development Milestones

316 Featured News & Press Releases

316 Appendix

325 Methodology

325 Coverage

325 Secondary Research

325 Primary Research

325 Expert Panel Validation

325 Contact Us

325 Disclaimer

Read More @http://www.idatainsights.com/reports-landing-page.php?id=124186/myocardial-infarction-pipeline-review-h2-2015

About Us:

iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.

Contact Us:
iData Insights

Tel: 1-866-237-2965

Web:http://www.idatainsights.com
Email: info@idatainsights.com

AboutiData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects.